Below 120 or Below 140? A Major Diabetes Trial Puts Blood Pressure Targets to the Test

How low should systolic blood pressure go in adults with type 2 diabetes? The OPTIMAL-DIABETES trial has renewed debate over the benefits and risks of intensive blood pressure control in diabetes. In this large randomized trial, a target below 120 mm Hg did not significantly reduce major cardiovascular events compared with a target below 140 mm Hg. Yet this result does not erase earlier evidence favoring tighter control. Instead, it reminds clinicians to consider the patient behind the reading.

Table of Contents

• What OPTIMAL-DIABETES found
• Why previous blood pressure trials differ
• Kidney outcomes and treatment safety
• Individualizing blood pressure targets
• Conclusion and FAQs

OPTIMAL-DIABETES Results: Below 120 vs. Below 140

The OPTIMAL-DIABETES trial, published November 7, 2026, enrolled 9,476 adults with type 2 diabetes and elevated cardiovascular risk at 33 sites in Brazil. Researchers assigned 4,745 people to a systolic target below 120 mm Hg and 4,731 to a target below 140 mm Hg. Importantly, these were treatment goals, not average readings.

After the first three months, mean systolic pressure was 121.8 mm Hg in the intensive group and 135.4 mm Hg in the standard group. Therefore, the treatment strategies produced a meaningful difference in blood pressure. Over four years, the primary cardiovascular outcome occurred in 6.0% of the intensive group and 6.7% of the standard group. Events included cardiovascular death, heart attack, stroke, and hospitalization for unstable angina or heart failure.

Although the result favored intensive treatment numerically, it was not statistically significant (hazard ratio 0.90; 95% confidence interval 0.77 to 1.06; P=0.20). In other words, a modest benefit remains possible. Also, the open-label design meant participants and clinicians knew the treatment assignment.

These findings raise an important question for clinical practice. If lower blood pressure does not consistently produce better cardiovascular outcomes, how aggressively should clinicians treat patients who already have multiple risk factors? The answer may depend on individual health conditions, treatment tolerance, and the potential risks of additional medication.

Why Blood Pressure Trials in Type 2 Diabetes Show Different Results

In the 2010 ACCORD BP trial, 4,733 adults with type 2 diabetes were assigned to similar systolic targets. Again, intensive treatment did not significantly reduce the main combined cardiovascular outcome. However, intensive treatment did reduce strokes, suggesting that some benefits may not appear in a broader outcome measure.

The picture changed with BPROAD, a Chinese trial reported in 2024. Among 12,821 adults with type 2 diabetes and high cardiovascular risk, intensive treatment reduced the primary cardiovascular outcome by 21% relative to standard treatment. Unlike OPTIMAL-DIABETES, this difference was statistically significant. Consequently, BPROAD strengthened support for lower targets in selected patients.

Why do these studies disagree? Their populations, follow-up periods, and outcome definitions were not identical. Differences in baseline cardiovascular risk, medication use, and achieved blood pressure may also influence results.

Furthermore, patients with diabetes often have additional conditions that affect their response to treatment. Kidney disease, prior cardiovascular events, and the duration of diabetes can all complicate clinical decisions. A strategy that benefits one population may offer less benefit in another.

A nonsignificant result does not prove that two strategies are equivalent. Therefore, clinicians should consider findings from multiple trials before recommending more aggressive blood pressure targets for patients with diabetes.

Kidney Outcomes and Treatment Safety Deserve Attention

Heart outcomes tell only part of the story. In OPTIMAL-DIABETES, kidney-related events occurred in 5.7% of intensive-treatment participants compared with 3.7% receiving standard care. Most involved reduced kidney function, while end-stage kidney disease was uncommon and similar between groups.

Meanwhile, serious adverse events overall were similar: 14.9% with intensive treatment and 14.6% with standard treatment. Thus, the kidney signal should not be mistaken for a rise in every serious complication. Earlier BPROAD findings also showed more symptomatic low blood pressure and elevated potassium with intensive treatment.

For clinicians, careful monitoring is essential. Likewise, questions about dizziness, falls, or lightheadedness on standing may reveal poor treatment tolerance. Patients with frailty, multiple medications, or limited mobility may face greater burdens from aggressive therapy.

Monitoring kidney function and electrolyte levels can help identify problems before they become serious. Additionally, reviewing medication combinations may reduce the likelihood of unwanted side effects. Patients should understand which symptoms to report and why follow-up appointments matter.

As a result, the safest goal is not always the lowest number. Treatment decisions should balance potential cardiovascular protection against the risks of lowering blood pressure too far.

Choosing an Individualized Blood Pressure Goal

The American Diabetes Association's 2026 Standards of Care recommend below 130/80 mm Hg when safely achievable. They also encourage a systolic goal below 120 mm Hg for patients with high cardiovascular or kidney risk. However, that guidance predates OPTIMAL-DIABETES, making a fresh discussion of benefits and risks worthwhile.

Start with cardiovascular history, kidney health, current readings, and symptoms. Next, consider medication burden, side effects, and patient preferences. For example, someone with previous heart disease who tolerates therapy may favor a lower goal. In contrast, a person with repeated falls may need a less aggressive approach.

Home readings can support decisions when office measurements vary. Additionally, consistent measurement techniques help clinicians distinguish persistent hypertension from occasional elevated readings. Patients may benefit from recording their results and discussing patterns with their healthcare team.

ACE inhibitors or angiotensin receptor blockers are particularly useful when diabetes occurs alongside albumin in the urine or coronary artery disease. Meanwhile, reducing dietary sodium, staying active, and managing weight remain important. These lifestyle measures support cardiovascular health regardless of the medication target.

For details on medication adjustments, see our guide to intensive blood pressure management.

Ultimately, choosing the right blood pressure target requires shared decision-making, careful monitoring, and regular follow-up. Patients seeking advice can speak with their care team or locate a clinician through Healthcare.pro.

Conclusion

OPTIMAL-DIABETES did not find a statistically significant cardiovascular advantage from a systolic target below 120 instead of below 140 mm Hg. Still, that result does not cancel the benefit reported in BPROAD.

The evidence favors personalized goals that account for cardiovascular risk, kidney health, treatment effects, and patient preferences. Rather than applying one target to everyone, clinicians should consider each patient's medical history and ability to tolerate treatment. Effective blood pressure control should also be safe and sustainable.

FAQs

1. Did OPTIMAL-DIABETES prove that below 120 mm Hg is ineffective?
   No. The difference was not statistically significant, but a modest cardiovascular benefit remains possible. The findings suggest that lower targets may not provide the same advantages for every patient.
2. Why did BPROAD show a benefit?
   BPROAD enrolled a different population and used a somewhat different outcome measure. Those differences may contribute, but no single explanation has been established. Researchers must consider the combined evidence to better understand which patients benefit most.
3. What target do current diabetes guidelines recommend?
   The 2026 ADA advises below 130/80 mm Hg when safe, while encouraging a systolic target below 120 for selected high-risk patients. However, treatment goals should reflect individual risk factors, medication tolerance, and clinical judgment.
4. Can intensive treatment affect the kidneys?
   Yes. OPTIMAL-DIABETES found more kidney-related outcomes with intensive treatment, reinforcing the need to monitor kidney function. Regular blood tests and medication reviews may help clinicians identify potential problems.
5. Should patients with type 2 diabetes change their blood pressure medications?
   Patients should not change or stop prescribed medications based on a single study. Instead, they should discuss their blood pressure readings, cardiovascular risk, kidney function, and treatment side effects with their healthcare professional.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.